89bio Announces Additional Data from the ENLIVEN Phase 2b

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated...

Related Keywords

San Francisco ,California ,United States ,Massachusetts ,Boston ,Sheryl Seapy ,Hank Mansbach ,Annie Chang ,Lifesci Advisors ,Nasdaq ,Drug Administration ,Linkedin ,Exchange Commission ,Liver Meeting ,Chief Medical Officer ,Non Invasive Tests ,Breakthrough Therapy ,New England Journal ,Breakthrough Therapy Designation ,Annual Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Sci Advisors ,Nasdaq Etnb ,89bio ,Nc ,